Antibacterial and antiplaque efficacy of a Lactoperoxidase-Thiocyanate-Hydrogen-Peroxide-System-Containing Lozenge
- Conditions
- Healthy patients
- Registration Number
- DRKS00022810
- Lead Sponsor
- Zentrum für Zahn-, Mund- und Kieferheilkunde der Universitätsmedizin Greifswald
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 16
female and male subjects who are at least 18 years old
• Present written declaration of consent
• Willingness and ability to meet the study requirements
• No systemic diseases, no use of antibiotics or medication in the last 6 months that would influence the Polymorphonuclear leukocytes function and/or salivary gland function and the salivary and sulcular fluid composition.
• No periodontal treatment in the last 6 months
• No pregnancy and breastfeeding
• No simultaneous participation in another clinical trial
• No smokers, alcohol, medication or drug addicts
• Taking antibiotics
• Pregnancy and breast-feeding period
• Simultaneous participation in another clinical trial
• lack of compliance
• Alcoholics, smokers, drug and drug addicts
• known hypersensitivity or allergies to the ingredients used in the chewing tablet, e.g. milk allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plaque inhibition: <br><br>According to the 4-day plaque regrowth study design, on day 5, the plaque regrowth is assessed with a disclosing solution (MIRA-2-TON®, Hager & Werken GmbH, Germany) and scored using Quigley & Hein plaque index (QHI) modified by Turesky et al. 1970.
- Secondary Outcome Measures
Name Time Method